CellCept 500mg Tablet contains mycophenolate mofetil 500mg, a prescription immunosuppressive medicine used in combination with other medicines to help prevent organ rejection following kidney, heart, and liver transplantation.
CellCept® is the reference brand containing mycophenolate mofetil. Mycophenolate mofetil is converted to mycophenolic acid in the body and suppresses the proliferation of certain immune cells involved in transplant rejection.
CellCept 500mg is a prescription transplant medicine and should be used only under the supervision of a transplant specialist or qualified healthcare professional. Regular medical and laboratory monitoring is important during treatment.
CellCept 500mg Tablet is an oral immunosuppressant containing mycophenolate mofetil 500mg.
It is prescribed as part of combination immunosuppressive therapy following organ transplantation. By reducing specific immune-cell activity, mycophenolate mofetil helps lower the risk of the immune system attacking and rejecting the transplanted organ.
CellCept 500mg is commonly used alongside other transplant medicines, such as a calcineurin inhibitor and corticosteroid, according to the patient’s individualized transplant regimen.
CellCept 500mg may be prescribed to help prevent rejection following:
It is generally administered as part of a combination immunosuppressive regimen.
CellCept contains mycophenolate mofetil, which is converted into mycophenolic acid (MPA) after administration.
MPA inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in purine synthesis. This particularly affects the proliferation of activated T and B lymphocytes.
By reducing the proliferation of these immune cells, mycophenolate mofetil suppresses the immune response responsible for attacking transplanted tissue and helps reduce the risk of organ rejection.
The appropriate CellCept dose depends on the type of transplant, the patient’s overall health, other immunosuppressive medicines, kidney or liver function, tolerability and the transplant team’s treatment protocol.
CellCept 500mg should be taken exactly as prescribed.
Do not increase, decrease or discontinue CellCept without consulting the transplant specialist. Maintaining the prescribed level of immunosuppression is important for preventing transplant rejection.
CellCept® is a branded medicine containing mycophenolate mofetil.
Authorized mycophenolate mofetil 500mg products manufactured by other pharmaceutical companies may contain the same active ingredient and strength. However, the manufacturer, inactive ingredients, formulation, packaging and regulatory status may differ.
Patients who have received an organ transplant should not switch between mycophenolate products without medical guidance.
Generic CellCept 500mg generally refers to an authorized mycophenolate mofetil 500mg product marketed as an alternative to CellCept where permitted by the relevant regulatory authority.
The principal commercial search relationship is:
CellCept 500mg → Mycophenolate Mofetil 500mg → Generic CellCept 500mg → Mycophenolate Mofetil 500mg Tablet → CellCept Alternative
Only describe a product as a generic equivalent where its regulatory status supports that claim.
CellCept 500mg and authorized mycophenolate mofetil alternatives are prescription medicines. Availability and dispensing requirements vary by market.
Customers searching for CellCept 500mg Tablet, Mycophenolate Mofetil 500mg, Generic CellCept 500mg, Mycophenolate Mofetil 500mg Tablet, Buy CellCept 500mg, CellCept 500mg Price, Generic Mycophenolate Mofetil and related commercial terms can check availability through appropriately licensed pharmacies and pharmaceutical suppliers.
Prescription, shipping and importation requirements differ across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.
CellCept 500mg contains mycophenolate mofetil and is used with other immunosuppressive medicines to help prevent organ rejection following kidney, heart or liver transplantation.
The generic name is mycophenolate mofetil 500mg.
Yes. CellCept is an immunosuppressant that reduces specific immune responses involved in transplant rejection.
CellCept is a branded product containing mycophenolate mofetil. Authorized generic mycophenolate mofetil products contain the same active ingredient, although product characteristics may differ.
Yes. Mycophenolate mofetil is used as part of immunosuppressive therapy to prevent rejection following kidney transplantation.
Yes. CellCept is indicated as part of an immunosuppressive regimen for prevention of rejection following heart transplantation.
Yes. CellCept is also used as part of combination immunosuppressive therapy following liver transplantation.
CellCept is prescription medicine. It should be obtained from an appropriately licensed pharmacy or pharmaceutical supplier and used under medical supervision.
Potential adverse effects include diarrhea, nausea, vomiting, abdominal discomfort and headache. Because mycophenolate suppresses the immune system, patients may also have an increased risk of infections.
Yes. Patients receiving mycophenolate mofetil generally require regular clinical follow-up and laboratory monitoring as directed by their transplant team.
No. Do not stop CellCept or change the prescribed dose without consulting your transplant specialist. Insufficient immunosuppression can increase the risk of organ rejection.
Mycophenolate mofetil can cause serious fetal harm. Patients who are pregnant, planning pregnancy or who could become pregnant should discuss the risks, pregnancy precautions and contraception requirements with their healthcare professional.
Medical Disclaimer: This product information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. CellCept (mycophenolate mofetil) is a prescription immunosuppressant requiring specialist supervision and regular monitoring. It can cause serious adverse effects, including infections and fetal harm. Always follow the prescribing information for the specific product and consult your transplant specialist or qualified healthcare professional before starting, stopping or changing treatment.
Last Updated: August 23, 2026
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Only logged in customers who have purchased this product may leave a review.
Mycophenolate Mofetil · Immunosuppressive Agents
YX Singapore (verified owner) –
Packing can improve, delivery ~10days. Trusted seller, product authentic.